ChromaDex : March 2021 Investor Presentation

WHO WE ARE

We are a global bioscience company dedicated to healthy aging.

The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.

ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex'spatent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available atwww.truniagen.com and through partnerships with global retailers and distributors.

This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2020 financial outlook, and which may be identified by the use of words like "expects," "assumes," "projects," "anticipates," "estimates," "we believe," "could be," "future" or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows and financial performance, business, business strategy, expansion, growth, products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook, and the timing and results of pre-clinical and clinical trials. Forward-looking statements are based on management's current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, "Item 1A. Risk Factors" of our

Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities Exchange Commission (the

SAFE HARBOR

STATEMENT

"Commission") on March 12, 2021, and in our other periodic filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Important factors that could cause actual results to differ materially from those in the forward looking statements include: the effect of the COVID-19 pandemic on our business, results of operations, financial condition and cash flows; a decline in general economic conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; inability to raise capital to fund continuing operations; changes in government regulation; and the ability to complete customer transactions and capital raising transactions.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

About Non-GAAP Financial Measures

ChromaDex's non-GAAP financial measures exclude interest, income tax, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense, bad debt expense related to Elysium Health and total legal expense for adjusted EBITDA excluding total legal expense. ChromaDex used these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. These non-GAAP measures should not be viewed in isolation from or as a substitute for ChromaDex's financial results in accordance with GAAP. Reconciliation of GAAP to non-GAAP measures are attached to this presentation.

FDA Disclaimer

Statements made in this presentation have not been evaluated by the Food and Drug Administration. ChromaDex products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors.

SAFE HARBOR STATEMENT

ChromaDex Investment Highlights

BOOSTING SUPPLEMENT

• • Total 2020 net sales of $59 million with $47 million of Tru Niagen® net sales

• • Tru Niagen® is the most efficient way to safely elevate NAD+

• • Safety profile backed by 11 clinical trials and global regulatory approvals

• • Strong IP protection with 20+ owned or licensed patents

1 PROVEN & PROPRIETARY NAD+ 3

STEADY E-COMMERCE GROWTH AND EXPANDING GLOBAL DISTRIBUTION FOOTPRINT

• • E-commerce represents ~60% of the business today, including North America, Europe, and Asia

• • Expanded to UK and Australia in 2020

• • Launching in Walmart U.S. in 2021

• • Strong blue-chip partners include A.S.

  Watson, Nestlé Health Science and W.R. Grace.

2 SIGNIFICANT OPPORTUNITY 4

DRIVEN BY TRENDS IN HEALTH & WELLNESS

• • Global anti-aging market of ~$410 billion with dietary supplements growing 6%(1)

• • Tru Niagen® gaining share in healthy aging and fitness categories; potential to expand to larger addressable markets

• • Exploring adjacent categories for Niagen® such as pet and infant nutrition

STRONG MOMENTUM AND FINANCIAL DISCIPLINE

• • Revenue CAGR of ~50% and gross margin increase from 48% to 60%+ since strategic pivot to focus on consumer product, Tru Niagen®(2)

• • Approaching cash flow break-even, as measured by Adjusted EBITDA excluding total legal expense(3)

• • Investing in brand building and R&D in 2021 given rapid growth in NAD+ market

• (1) ChromaDex estimates. See slide 23 for details

• (2) Period from Q1 2017 to Q4 2020. Quarterly sales.

• (3) Non-GAAP metric. See slide 37 for details.